Testing the Persuasiveness of Pro-inoculation Arguments

July 7, 2023 updated by: University of Pennsylvania

Message Testing Protocol for Misinformation Concerns

The investigators will recruit a national sample of parents of 7-10-year-olds to complete an argument strength ranking for either a simple forwarding message or between 3 and 6 randomly selected arguments from an overall set of 50 to 100 messages identified from various online sources. Parents will rate each message they see on measures of perceived argument strength/PME. Parents will also answer sociodemographic questions and then rank the believability of a set of anti-vaccine messages identified in a different study. Study findings will contribute valuable information to understanding the effectiveness of different inoculation messages.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

523

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • United States
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19104
        • UPenn
        • Contact:
          • Jennifer Morgan

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  1. Male or female parent or legal guardian of an adolescent ages 7-10
  2. Age eligible child has not yet received any doses of the HPV vaccine
  3. Resides in the United States
  4. English speaking
  5. Completed informed consent

Exclusion Criteria:

  1. Unable to read English at a 6th grade literacy level
  2. Age < 18
  3. Does not have a child within the age range of 7-10
  4. Age-eligible child has received 1 or more doses of the HPV vaccine
  5. Does not have a social media account on one or more of the following platforms OR does not read online news stories: Twitter, Instagram, YouTube, Facebook (feasibility testing only - survey participation will not have this exclusion criteria)
  6. Unwilling or unable to provide informed consent to study participation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Simple forewarning message
Participants will receive a simple short forewarning message to read and rate.
Behavioral: Simple forewarning message
Participants will be presented with a simple forewarning message.
Experimental: Argument inoculation messages
Participants will view a random sample of 3 text-only short messages (from a corpus of 100 arguments) to read and rate.
Behavioral: Argument inoculation messages
Participants will then be presented with arguments randomly selected by the Qualtrics software algorithm from the full set of messages.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Argument strength/PME
Time Frame: The outcome measure will be assessed immediately after the participant has viewed each pro-HPV vaccine message if they are in the multiple message condition, or the simple message if they are in the simple message condition stimuli during the survey.
Arguments will be rated for their argument strength/message effectiveness
The outcome measure will be assessed immediately after the participant has viewed each pro-HPV vaccine message if they are in the multiple message condition, or the simple message if they are in the simple message condition stimuli during the survey.
Misinformation believability
Time Frame: The outcome measure will be assessed immediately after the participant has viewed each misinformation message during the survey.
A rating of the believability/ credibility of vaccine misinformation
The outcome measure will be assessed immediately after the participant has viewed each misinformation message during the survey.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Pennsylvania

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 4, 2023

Primary Completion (Actual)

May 24, 2023

Study Completion (Actual)

May 24, 2023

Study Registration Dates

First Submitted

October 20, 2022

First Submitted That Met QC Criteria

April 5, 2023

First Posted (Actual)

April 7, 2023

Study Record Updates

Last Update Posted (Actual)

July 11, 2023

Last Update Submitted That Met QC Criteria

July 7, 2023

Last Verified

July 1, 2023

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • dfjgehea

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Vaccine Refusal

Clinical Trials on Simple forewarning message

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burundi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe